- ADELSMAYR Gabriel
- AGHAZARIAN Artin
- BAUER David
- BEIGLBÖCK Hannes
- BERNER Carolin
- BINDER Christoph
- BRUSILOVSKAYA Ksenia
- BUCSICS Theresa
- CHROMY David
- DIARRA Danielle
- DIXON Emmanuel Dauda
- DEISCHINGER Carola
- FALCONE Veronica
- FELSENREICH Daniel Moritz
- FELLINGER Paul
- FISCHER Arabella
- FÖSSLEITNER Philipp
- GERNER Marlene
- GISINGER Teresa
- HAGER Marlene
- HASENÖHRL Timothy
- HEDESAN Oana
- HERZ Carsten
- HOFER Benedikt
- KALTENECKER Christopher
- KOCH Marianne
- KOGLER Hubert
- KÖNIGSHOFER Philipp
- LEITNER Miriam Kristin
- LEUTNER Michael
- LISCHKA Julia
- MARSCHALEK Marie-Louise
- MECHTLER Thomas
- METZ Matthäus
- PALMA Stefano
- PANIC-JANKOVIC Tanja
- PATEISKY Petra
- PATERNOSTRO Rafael
- PERRICOS Alexandra
- PFISTERER Nikolaus
- POGLITSCH Marcus
- RADUN Richard
- RANZENBERGER-HAIDER Tamara
- REISCHER Theresa
- RIEDL Florian
- ROZMARIC Tomaz
- SCHÄFER Bhavapriya
- SCHAUER Ingrid
- SCHEINER Bernhard
- SCHERR Stefan
- SCHMIDBAUER Caroline
- SIMBRUNNER Benedikt
- SPRINGER Stephanie
- STAUFER Katharina
- STEINACHER Daniel
- TAGHIZADEH WAGHEFI Hossein
- TEUFELHART Manuela
- THANHÄUSER Margarita
- Former Students
STEINACHER Daniel
Supervisor: Michael Trauner
Committee: Michael Krebs, Harald Esterbauer
Department: Internal Medicine III, Clinical Division of Hepatology
E-mail: daniel.steinacher@meduniwien.ac.at
Tel: +43 (0)1 40400 - 61590
Homepage: http://www.meduniwien.ac.at/innere3/
Current academic degree: Cand.med.
Previous University and Subject: Medical University of Vienna, Human Medicine
Thesis since: 10/2013
Characterization of Metabolic and Therapeutic Properties of Modified Bile Acid Derivatives
Prevalence of nonalcoholic fatty liver disease (NAFLD) - a spectrum of liver diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) leading to liver cirrhosis and hepatocellular carcinoma (HCC) - is increasing. Bile acids (BA) could constitute a new therapeutic option. BA can improve liver damages in a mouse model for liver diseases by stimulating biliary HCO3 secretion, reducing inflammation, fibrosis and apoptosis. Therefore, we want to investigate bile acids in mouse models of liver diseases.
Methods and Skills:
Western blot; histology; real time PCR; metabolic cages
